Skip to the content

pharmaceutical daily

Pharmaceuticals, Biotechnology and Life Sciences

  • HOME
  • Pharma Business
  • About us
    • Media Kit
    • Privacy Policy
  • Contact
Study findings on mineral excipient for enhanced ODTs
June 7, 2018 Off

Study findings on mineral excipient for enhanced ODTs

By Dino Mustafić

In a recent study, scientists confirmed the ability of Omyapharm to formulate orally disintegrating tablets (ODTs) with enhanced mouthfeel and…

June 7, 2018 Off

Allergan and actress Shay Mitchell join forces to inspire women to know their birth control

By Dino Mustafić

Allerganhas launched ‘BC Trivia’ featuring actress and new ambassador Shay Mitchell – a fun and engaging trivia quiz designed to…

Schreiner MediPharm develops smart blister pack for clinical trial
June 6, 2018 Off

Schreiner MediPharm develops smart blister pack for clinical trial

By Dino Mustafić

Schreiner MediPharm developed a smart blister pack for a multinational pharmaceutical corporation, for digital patient compliance monitoring to enhance medication…

Alkermes net $50 million from Biogen in connection with multiple sclerosis drug BIIB098
June 6, 2018 Off

Alkermes net $50 million from Biogen in connection with multiple sclerosis drug BIIB098

By Dino Mustafić

Alkermes has received a $50 million payment from Biogen after it reviewed the preliminary gastrointestinal tolerability data from the ongoing…

FDA approves Mylan’s drug that helps reduce the risk of infection during cancer treatment
June 5, 2018 Off

FDA approves Mylan’s drug that helps reduce the risk of infection during cancer treatment

By Dino Mustafić

The U.S. Food and Drug Administration has approved Mylan’s Fulphila (pegfilgrastim-jmdb) as the first biosimilar to Neulasta (pegfilgrastim) to decrease the chance…

Bayer plans closing of Monsanto acquisition on June 7
June 4, 2018 Off

Bayer plans closing of Monsanto acquisition on June 7

By Dino Mustafić

Bayer plans to complete the acquisition of Monsanto on June, 7, doubling the size of its agriculture business, the company…

Novartis to seek approval of Kisqali plus fulvestrant for postmenopausal women with advanced breast cancer
June 4, 2018 Off

Novartis to seek approval of Kisqali plus fulvestrant for postmenopausal women with advanced breast cancer

By Dino Mustafić

Novartis on Sunday announced positive results from the third Phase III trial of Kisqali in advanced or metastatic breast cancer.

FibroGen’s pamrevlumab+chemotherapy could be neoadjuvant treatment regimen for certain advanced pancreatic cancer
June 4, 2018 Off

FibroGen’s pamrevlumab+chemotherapy could be neoadjuvant treatment regimen for certain advanced pancreatic cancer

By Dino Mustafić

FibroGen, a biopharmaceutical company, on Monday said the results from the Phase 1/2 clinical trial, testing pamrevlumab in combination with…

Celgene’s Relevance trial add further to the understanding of the R2 regimen in patients with follicular lymphoma
June 4, 2018 Off

Celgene’s Relevance trial add further to the understanding of the R2 regimen in patients with follicular lymphoma

By Dino Mustafić

Celgene Corporation’s study testing Revlimid on patients with previously untreated follicular lymphoma showed that treatment with a chemotherapy-free R2 regimen offered numerically…

Novartis’s first targeted migraine prevention therapy to patients in Europe
June 1, 2018 Off

Novartis’s first targeted migraine prevention therapy to patients in Europe

By Dino Mustafić

Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended approval for Novartis’s Aimovig…

Posts pagination

Previous 1 … 3,387 3,388 3,389 … 3,606 Next

JOIN OUR COMMUNITY

Proudly powered by WordPress | Theme: Envo Magazine